Kliniken der Stadt Koeln gGmbH
- Address
- lock Available on a paid plan
Respiratory Tract Diseases
The department is evaluating new oral agents for Idiopathic Pulmonary Fibrosis, with the goal of slowing disease progression and preserving lung capacity.
- Oral MBS2320 assessment in IPF
- Impact on forced vital capacity
- Safety profile compared with placebo
Research is conducted at Kliniken der Stadt Koeln gGmbH in Cologne, Germany, involving 26 investigators and a total of five active trials.
Eye Diseases
A focused study on Neurotrophic Keratopathy examines a novel ophthalmic solution designed to promote corneal healing and maintain visual function.
- RGN-259 ophthalmic solution safety and efficacy
- Double‑blind placebo‑controlled design
- Central review of corneal outcomes
The trial takes place within the Department of Anesthesiology and Critical Care Medicine at Merheim Medical Center, supporting multidisciplinary patient care.
Neoplasms
Ongoing investigations target Resectable Stage II‑IIIB Non‑small cell lung cancer and Unresectable Pleural Mesothelioma, testing innovative immunotherapy‑chemo combinations to improve overall survival.
- Volrustomig with carboplatin/pemetrexed versus standard of care
- Pre‑ and postoperative nivolumab integration
- Event‑free survival assessment by blinded review
These oncology trials are coordinated at the Merheim campus, leveraging the expertise of 26 investigators across the institution.
Disorders of Environmental Origin
A critical‑care trial evaluates high‑dose intravenous vitamin C for severe burn patients, aiming to reduce persistent organ dysfunction and mortality when added to standard therapy.
- High‑dose vitamin C infusion protocol
- 28‑day composite outcome of organ dysfunction and mortality
- Placebo‑controlled randomized design
Conducted at the Merheim Medical Center, the study benefits from the department’s extensive experience in managing complex trauma cases.
Bacterial Infections and Mycoses
While current trials emphasize oncology and respiratory disease, the department retains strong capabilities in treating infection‑related complications in critical care, laying groundwork for future antimicrobial studies.
- Critical‑care infection monitoring
- Integration of antimicrobial guidelines
- Readiness for future bacterial/mycotic trial enrollment
The facility’s comprehensive infection management program supports patient safety and positions the site for upcoming research initiatives.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 12 therapeutic areas and 15 of 147 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 133 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 25 by active trials.
- 1AstraZeneca AB6active
lock +24 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB13trials
lock +11 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Kliniken der Stadt Koeln gGmbH
lock Showing 1 of 79 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy plus Nivolumab versus Neoadjuvant Chemotherapy plus Placebo, followed by Surgical Resection and Adjuvant Treatment with Nivolumab or Placebo for Participants with Resectable Stage II-IIIB Non-small Cell Lung Cancer (CheckMate 77T, CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 77T) | Bristol-Myers Squibb Services Unlimited Company | Phase III | Not Recruiting | Sep 2019 | — |
IMP list
lock Showing 1 of 147 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cisplatin | 24 | Unknown | 2015-11-20 | 2026-06-10 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.